Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2021
Event: Entry into a Material Definitive Agreement for the acquisition of substantially all assets of GenArraytion, Inc.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics are not provided in this document.
- Transaction Value: Aggregate purchase price of $1.2 million.
- Consideration: Issuance of 123,981 shares of common stock ($0.001 par value).
- Share Structure: 50% issued without forfeiture risk; 50% subject to forfeiture risk pending completion of intellectual property transition services.
- Future Obligations: Royalty payments to GenArraytion based on net sales of acquired products over the next five years.
Material Changes
The primary material change is the expansion of the Company's asset base through the acquisition of GenArraytion, Inc. The Company has incurred a new contingent liability in the form of future royalty payments and has increased its outstanding share count by 123,981 shares.
Outlook, Risks, and Contingencies
- Contingent Consideration: Half of the issued shares are subject to forfeiture if intellectual property transition services are not satisfactorily completed.
- Future Cash Outflows: The Company is obligated to make royalty payments based on net sales of GenArraytion products for five years.
- Regulatory Compliance: The Company agreed to file a registration statement for the issued shares within sixty days of the agreement date.
- Indemnification: GenArraytion has agreed to customary indemnification obligations for a one-year period ending July 9, 2022.
Investor Verification Checklist
- Verify the exact terms of the "intellectual property transition services" required to vest the 50% of shares subject to forfeiture.
- Review the upcoming Form 10-Q for the quarter ended September 30, 2021, for the full text of the Asset Purchase Agreement.
- Monitor the filing of the registration statement for the 123,981 shares issued to GenArraytion within the 60-day window.
- Assess the potential impact of the five-year royalty obligation on future gross margins for the acquired product line.